Clinical trial · Observational
Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective/prospective observational multicentric trial on patients with bone metastases from NENs. General objectives: * To trace on a national scale the frequency of bone metastases in patients with neuroendocrine neoplasm (NEN) and their clinical management. * To correlate clinical and biological factors to clinical outcomes. * To centralise and to make homogeneous clinical, pathological, instrumental and therapeutic information. * To set up a database and to acquire biological material for studying predictive and prognostic biomarkers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Metastases | — | UNRESOLVED | — |
| Neuroendocrine Neoplasm | Neuroendocrine Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Overall survival
- timeFrame
- 01/2021 - 12/2021
- description
- Overall survival (OS) will be calculated from the date of BM diagnosis to the date of death
- measure
- Influence of skeletal related events (SRE) on survival
- timeFrame
- 01/2021 - 12/2021
- description
- Influence of skeletal related events (SRE) on overall survival (OS)
- measure
- Correlation between SRE and time from bone metastasis and SRE, site of one metastases, number of bone metastases, morphology of bone metastases, LDH
- timeFrame
- 01/2021 - 12/2021
- description
- To evaluate the correlation between SRE and time from bone metastasis and SRE, site of one metastases, number of bone metastases, morphology of bone metastases, LDH
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of NEN * Instrumental and/or histological diagnosis of bone metastasis * At least one year of follow-up from the diagnosis of bone metastasis Exclusion Criteria: * Small cell lung carcinoma * MiNEN * Non neuroendocrine neoplasm
References
Publications (2)
- RESULTHarding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK. Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024. PMID 29295881
- RESULTGrisanti S, Bianchi S, Locati LD, Triggiani L, Vecchio S, Bonetta A, Bergamini C, Conte P, Airoldi M, Merlano M, Carlini P, Ibrahim T, Rossetto C, Alfieri S, Pronzato P, Tonoli S, Maroldi R, Nicolai P, Resteghini C, Magrini SM, Berruti A. Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. PLoS One. 2019 Mar 20;14(3):e0213934. doi: 10.1371/journal.pone.0213934. eCollection 2019. PMID 30893350